Sana Biotechnology (SANA) Projected to Post Quarterly Earnings on Thursday

Sana Biotechnology (NASDAQ:SANA) is expected to be posting its quarterly earnings results before the market opens on Thursday, March 6th. Analysts expect Sana Biotechnology to post earnings of ($0.22) per share for the quarter.

Sana Biotechnology Stock Performance

Sana Biotechnology stock opened at $2.43 on Tuesday. The stock has a market capitalization of $542.54 million, a price-to-earnings ratio of -1.74 and a beta of 1.60. Sana Biotechnology has a 52-week low of $1.52 and a 52-week high of $11.48. The stock’s 50 day moving average price is $2.85 and its two-hundred day moving average price is $3.43.

Wall Street Analysts Forecast Growth

SANA has been the subject of a number of analyst reports. JMP Securities lowered Sana Biotechnology from an “outperform” rating to a “market perform” rating in a research report on Tuesday, November 5th. TD Cowen upgraded Sana Biotechnology from a “hold” rating to a “buy” rating in a research note on Wednesday, January 8th. Finally, HC Wainwright raised their target price on Sana Biotechnology from $8.00 to $11.00 and gave the stock a “buy” rating in a research note on Wednesday, January 8th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $14.00.

Insider Activity at Sana Biotechnology

In other Sana Biotechnology news, insider Fmr Llc sold 290,912 shares of Sana Biotechnology stock in a transaction on Wednesday, January 8th. The stock was sold at an average price of $6.49, for a total transaction of $1,888,018.88. Following the completion of the transaction, the insider now owns 4,541,511 shares in the company, valued at approximately $29,474,406.39. The trade was a 6.02 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 31.10% of the stock is currently owned by corporate insiders.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.